source
- PepGen reports positive Phase 2 data for PGN-EDODM1 in myotonic dystrophyPepGen disclosed that its experimental oligonucleotide therapy PGN-EDODM1 showed encouraging early signals in a Phase 2 cohort of patients with myotonic dystrophy type 1 (DM1). The company said the…
- Coherus Oncology cuts 30% of staff to focus on esophageal cancer comboCoherus Oncology announced another round of layoffs, reducing its workforce by about 30% as it narrows its development program. The cuts follow the presentation of phase 1b data on a combination o…